new
   Side Effects of Aceclidine Eye Drops (Aceclidine)
502
Dec 12, 2025

Aceclidine Eye Drops (Aceclidine) is a novel cholinergic agonist first approved in the United States in 2025, specifically indicated for the treatment of presbyopia in adults. As a prescription medication, a comprehensive understanding of its side effect profile, risks of serious adverse reactions, and usage precautions is crucial for medication safety and therapeutic efficacy.

Side Effects of Aceclidine Eye Drops (Aceclidine)

Local Irritant Reactions

Instillation site irritation: 20%.

Dim vision: 16%.

Headache: 13%.

Other adverse reactions with an incidence rate above 5% include conjunctival hyperemia (8%) and ocular hyperemia (7%).

Transient Effects on Visual Function

Temporary changes in visual function may occur after drug administration, mainly manifested as blurred vision and dimness.

Such reactions stem from the drug's impact on the eye's accommodation mechanism, typically being most pronounced within a period after administration and then gradually subsiding.

Patients need to pay special attention to avoiding driving or operating machinery when vision is unclear, and exercise extreme caution when engaging in hazardous activities such as night driving or working in poorly lit environments.

Serious Side Effects of Aceclidine Eye Drops (Aceclidine)

Risk of Retinal Complications

As a miotic, aceclidine has been rarely reported to cause serious adverse reactions such as retinal tears and retinal detachment in susceptible individuals and patients with pre-existing retinal lesions.

Although the incidence of such complications is low, the consequences are severe and may result in permanent visual impairment.

A baseline retinal examination is recommended for all patients before initiating treatment.

Warning signs include sudden onset of photopsia, floaters, or vision loss.

Once these symptoms appear, patients should seek immediate professional medical assistance for timely diagnosis and intervention.

Risk of Exacerbated Ocular Inflammation

For patients with a history of iritis, the use of miotics may exacerbate ocular inflammatory sequelae, particularly the formation of adhesions between the iris and lens (posterior synechiae).

Such patients must use the drug under close medical monitoring, with a full weighing of the therapeutic benefits against potential risks.

Possibility of Allergic Reactions

The drug is not recommended for patients with known hypersensitivity to aceclidine or any component of Aceclidine Eye Drops.

In clinical practice, detailed inquiries should be made about the patient’s drug allergy history, especially previous adverse reactions to ophthalmic medications.

Precautions for Aceclidine Eye Drops (Aceclidine)

Correct Administration Method

The recommended dosage of Aceclidine Eye Drops is one drop per eye, once daily.

After waiting for 2 minutes, instill a second drop into the same eye using the same single-dose vial.

Contact Lens Usage Guidelines

Contact lenses should be removed before instilling aceclidine, and can be reinserted 10 minutes after instillation.

This time interval is established based on the absorption and distribution characteristics of the drug in the eye, which can effectively reduce interactions between the drug and lens materials.

Combined Medication Management

If the patient is using multiple topical ophthalmic medications, an interval of at least 5 minutes should be maintained between the administration of different products.

This sequential administration method avoids physical interactions between drugs and ensures the adequate absorption and efficacy of each medication.

Storage and Handling Key Points

Storage conditions: The drug must be stored refrigerated at 2°C to 8°C, and freezing should be avoided.

Room temperature use: Once removed from refrigeration, it can be stored at room temperature (maximum 25°C) but must be used within 30 days.

To prevent ocular injury or contamination, care should be taken to avoid contact between the single-dose vial and the eye or any other surface during use.

Opened single-dose vials should be discarded immediately after use and must not be reused.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
RELATED ARTICLES
Dosage and Administration, Recommended Dose of Elacestrant (Orserdu)

Elacestrant (Orserdu) is a selective estrogen receptor degrader (SERD), which provides an important treatment option...

Friday, December 19th, 2025, 11:49
What Are the Indications for Elacestrant (Orserdu)?

Elacestrant (Orserdu) is a novel endocrine therapy agent that demonstrates significant value in the treatment of...

Friday, December 19th, 2025, 11:40
What Are the Purchase Channels for Elacestrant (Orserdu)?

With the advancement of medical technology, elacestrant (Orserdu), a targeted drug for breast cancer with specific...

Friday, December 19th, 2025, 11:38
Adverse Reactions of Capmatinib (Tabrecta)

Capmatinib (Tabrecta) is a highly selective MET inhibitor indicated for the treatment of patients with advanced...

Friday, December 19th, 2025, 11:35
RELATED MEDICATIONS
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved